NASDAQ false 0001369568 0001369568 2021-06-29 2021-06-29





Washington, D.C. 20549









Date of Report (Date of Earliest Event Reported): June 29, 2021




(Exact Name Of Registrant As Specified In Its Charter)




Delaware   001-33057   76-0837053
(State or other jurisdiction
of incorporation)
File Number)
  (I.R.S. Employer
Identification No.)


355 Alhambra Circle

Suite 801

Coral Gables, Florida

(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (305) 420-3200

Not Applicable

Former Name or Former address, if changed since last report



Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class


Name of Exchange
on Which Registered



Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers



Election of New Directors

The Board of Directors (the “Board”) of Catalyst Pharmaceuticals, Inc. (the “Company”), in conformity with the Company’s bylaws, has increased the size of the Board from six members to seven members and has appointed Molly Harper to fill the vacancy on the Board. Ms. Harper will serve until the Company’s 2021 annual meeting of stockholders or until her resignation or death, if earlier.

There is no family relationship between Ms. Harper, on the one hand, and any of the Company’s other officers or directors, on the other hand. Further, there are no understandings or arrangements between Ms. Harper, on the one hand, and any other person, on the other hand, pursuant to which Ms. Harper was selected as a director. Finally, there have been no transactions, since the beginning of the Company’s last fiscal year, or any currently proposed transactions, in which the Company was or is to be a participant and as to which the amount exceed $120,000, in which Ms. Harper had or will have a direct or indirect material interest. Ms. Harper has not yet been appointed to any committees of the Board.

On June 29, 2021, the Company issued a press release announcing the appointment of Ms. Harper to the Board. The press release is attached as Exhibit 99.1 to this Current Report on Form 10-K and is incorporated herein by reference.


Item 9.01

Financial Statements and Exhibits.





99.1    Press release issued by the Company on June 29, 2021.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)




Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Catalyst Pharmaceuticals, Inc.

/s/ Alicia Grande

              Alicia Grande
              Vice President, Treasurer and CFO

Dated: June 29, 2021




Exhibit 99.1



Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors

CORAL GABLES, Fla., June 29, 2021 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced the appointment of Molly Harper to the Company’s Board of Directors.

“On behalf of the Board of Directors, I am very pleased to welcome Ms. Harper to the Catalyst board. Ms. Harper is a highly accomplished life-science executive with broad background in rare disease drug development, commercialization and strategic planning across a diverse range of therapeutic areas. Her experience is well suited to further strengthen our Board of Directors and will serve the Company well as we continue to execute our growth strategy,” said Patrick J. McEnany, Chairman and CEO of Catalyst.

“I am excited to be joining the Board of Directors of Catalyst at such a pivotal time in the company’s evolution, as it continues its effort to broaden its portfolio and product pipeline,” said Ms. Harper. “I am looking forward to working with the Board and the Company’s senior leaders, as we continue our mission of changing the lives of patients and their families suffering from rare diseases.”

Ms. Harper has over 20 years of experience focusing on strategic planning and cross-functional leadership at life sciences companies of all sizes. Since May 2020, Ms. Harper has served as Executive Vice President of Operations for Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system. Prior to joining Relmada, Ms. Harper served in positions of increasing responsibility with Akcea Therapeutics, a development and commercialization company focused on rare diseases, where she was most recently Senior Vice President and Global Franchise General Manager with cross-functional responsibility for a six-drug portfolio including two approved rare disease drugs. She was one of the first employees at Akcea, which she joined as VP of Commercial Development. Prior to joining Akcea, Ms. Harper was Head of US Endocrinology in the Rare Disease division of Sanofi Genzyme. Ms. Harper’s experience at Genzyme included global and U.S. marketing leadership positions, and she previously held positions across sales and marketing in both primary care and hospital businesses at Merck & Co. Prior to joining Merck, Ms. Harper worked in life sciences equity research at UBS Warburg, and as a strategy consultant with The Wilkerson Group/IBM.

Ms. Harper received her Bachelor of Arts from Cornell University and her Master of Business Administration from the Wharton School of the University of Pennsylvania. Ms. Harper also serves on the Board of Directors of PreciseDx, a privately held oncology AI pathology company.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst’s New Drug Application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was approved in 2018 by the U.S. Food & Drug Administration (“FDA”), and Firdapse® is commercially available in the United States as a treatment for adults with LEMS. Further, Canada’s national healthcare regulatory agency, Health Canada, recently approved the use of Firdapse® (amifampridine) for the treatment of patients in Canada with LEMS.

Firdapse® is currently being evaluated in clinical trials for the treatment of MuSK-MG and has received Orphan Drug Designation from the FDA for myasthenia gravis.

Catalyst’s Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst’s Annual Report on Form 10-K for fiscal year 2020 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst’s filings with the SEC are available from the SEC, may be found on Catalyst’s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.


Media Contact    Company Contact
David Schull    Patrick J. McEnany
Russo Partners    Catalyst Pharmaceuticals
(212) 845-4271    Chief Executive Officer
david.schull@russopartnersllc.com    (305) 420-3200